This followed the active pharmaceutical ingredient (API) manufacturer's strong earnings print in Q4FY24.
The pharma firm's stock ended the day with gains of 3.2 per cent at ₹4,222 a share.
While analysts said they were positive about the firm's performance and its FY25 commentary, they said the stock price might see some downsides amid rich valuation.
The March quarter of FY24 saw the company's net profit rise 67 per cent to ₹538 crore compared to ₹321 crore in the corresponding period last year. Its revenue grew 18 per cent to 2,303 crore.
Denne historien er fra May 28, 2024-utgaven av Business Standard.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra May 28, 2024-utgaven av Business Standard.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Technology changes BFSI sector
Firms in the industry are undergoing a major digital transformation, with technologies - Cloud, Al, GenAI, RPA, and blockchain - leading the way, says a Business Standard-Everest Group report
Making sense of India's real estate boom
Growth drivers in real estate include urbanisation, disposable incomes, and demand for residential, commercial, and logistics spaces, according to a Business Standard-Knight Frank report
THE BIGGEST BFSI SUMMIT IS EVEN BIGGER NOW
The largest financial sector event in the country - the Business Standard BFSI Insight Summit - is back this year in a bigger form.
Shares of Adani Ports anchor at 5-month low
Down 5% in two days after business update for October
Markets rebound as investors cast wide net for value
In-demand financial stocks drive the rally
Global mkt: Stocks, Treasury yields gain as US votes
World stocks rose and Treasury yields rebounded on Tuesday while an index of market volatility retreated, as markets awaited early indications of the outcome of a knife-edge US election, with only currency markets showing some jitters.
Upper-teens EPS growth likely for Gland Pharma in next two financial yrs
Gland Pharma's Q2FY25 results beat muted expectations, with upper-teens EPS growth projected over the next two financial years despite a slowdown in US sales and temporary issues at its Cenexi subsidiary.
Sagility India IPO booked 22% on Day 1
The initial public offering (IPO) of Sagility India Ltd, a technology-enabled services provider in the health care space, received 22 per cent subscription on the first day of bidding on Tuesday.
Record FPI exodus throws a shadow on stock markets
Foreign investors are souring on India's stock market, selling a record amount of shares amid signs the South Asian nation's post-pandemic economic boom is losing steam.
Govt may divest 2.5% in HZL through OFS
The Centre is planning to sell 2.5 per cent of the total share capital of Hindustan Zinc Ltd (HZL) through an offer for sale (OFS) on Wednesday and Thursday for ₹505 per share.
